Medicaid Rx Whistleblower Cases To Increase After Bayer Settlement - DoJ
Executive Summary
Medicaid reimbursement false claim suits are expected to increase as a result of the recent Bayer settlement, Department of Justice Civil Fraud trial attorney Reed Stephens told the New York State Bar Association's annual meeting Jan. 23 in New York City.
You may also be interested in...
HCFA Reform, Drug Pricing Protections Urged Prior To Medicare Expansion
Health Care Financing Administration reform must precede the adoption of a Medicare prescription drug benefit, Commerce Committee Chairman Bliley (R-Va.) declared in a Sept. 25 letter to HCFA Administrator Nancy-Ann DeParle.
Bayer Drug Prices To Be Monitored By HHS Under Medicaid Fraud Settlement
Bayer will provide states and the federal government with the average selling prices of its drugs to help them set reasonable reimbursement rates under a tentative settlement agreement with the Justice Department.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011